We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Handheld Immunoanalyzer Performs Laboratory Tests near Patient without Sacrificing Sensitivity and Precision

By LabMedica International staff writers
Posted on 22 Mar 2023

Near Patient Testing (NPT), also known as Point of Care Testing (POCT), is a rapidly growing area within the field of In vitro diagnostics (IVDs). More...

NPT is now recognized for its key role in making services more patient-centered by bringing diagnostic testing closer to the patient. This shift has the potential to significantly transform the way healthcare services are delivered to patients. By enabling timely diagnosis at the bedside, in community settings, or even in general practice, the delivery of care can be made much more efficient, allowing patients to receive the right diagnosis and treatment in a timely and convenient manner. Now, a handheld portable immunoanalyzer with the sensitivity and precision of centralized laboratory equipment is currently being developed in a form factor suitable for low-cost, point-of-care testing anywhere in the world.

Proxim Diagnostics Corp. (Santa Clara, CA, USA) is developing the Profile System, a portable and fully automated immunodiagnostic device that can run several types of multiplexed assays using disposable cartridges. The system performs critical laboratory tests near the patient using whole blood without sacrificing sensitivity and precision to deliver the most critical information to the doctors right when they need it. The Profile System is battery operated, and offers a touch-screen display interface, along with wireless, Ethernet, and USB connectivity.

The handheld device is expected to enhance the ability of clinicians to perform rapid, high-quality testing at the point of care, such as in emergency rooms, intensive care units, nursing homes, community/remote clinics and in-home care, as well as in disaster relief and defense situations. The system is currently available for research use only. Proxim is also developing several immunoassays for sepsis, cardiology, and infectious diseases that can match the sensitivity and precision of tests that are run on larger, centralized laboratory equipment.

Related Links:
Proxim Diagnostics Corp.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.